Helix' fiscal 3rd-qtr loss grows 7% to $1.5M

24 June 2007

Canadian drugmaker Helix BioPharma recorded a loss of C$1.5 million ($1.41 million), or C$0.04 per common share, for the third quarter of its fiscal year, ended April 30, 2007, an increase of 7% on the deficit it reported for the year-earlier comparable period. The firm said that costs associated with a shareholder proxy dispute, increased R&D expenditure and the higher operating costs were responsible for the growing loss.

Helix also reported that its revenues for the period were C$864,000, down 21.4%, which it attributed to a reduction in the sale of the osteoarthritis treatment Orthovisc (hyaluronic acid) and the lack of license fees from its biochip technology. Despite the decline, the firm said that a reduction in the cost of sales, down 12.3% to C$249,000 and favorable exchange rates, had allowed it to maintain its overall margins.

In addition, Helix's operating general and administration costs for the period fell 6.8% to C$1.0 million due to lower sales commissions and a drop in its expenditure on wages, travel and marketing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight